Arch Biopartners Announces Alberta Health Services Approval to Proceed with Phase II Trial for LSALT Peptide Targeting Cardiac Surgery-Associated Acute Kidney Injury (CS-AKI)
September 11, 2024 06:30 ET
|
Arch Biopartners
TORONTO, Sept. 11, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that Alberta Health Services (AHS) has approved the...
STOCKHOLDER INVESTIGATION: The M&A Class Action Firm Investigates the Merger of Arch Resources, Inc. – ARCH
August 21, 2024 12:12 ET
|
Monteverde & Associates PC
NEW YORK, Aug. 21, 2024 (GLOBE NEWSWIRE) -- Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022...
Triyam Recognized on Inc. 5000 List for the Fourth Consecutive Year
August 15, 2024 09:00 ET
|
Access Information Management Shared Services, LLC
Company ranking leveled up 999 spots on this highlighted list of America’s Fastest-Growing Private Companies
Arch Biopartners’ Cilastatin Drug Candidate to Participate in the PONTIAC Phase II Trial Targeting Acute Kidney Injury Caused by Drug Toxins
August 02, 2024 07:20 ET
|
Arch Biopartners
Arch is repurposing cilastatin, a dipeptidase-1 inhibitor, as a new treatment for acute kidney injury (AKI)Cilastatin is particularly well suited to prevent AKI caused by drug toxins due to its unique...
Arch Biopartners Closes Non-Brokered Private Placement
July 30, 2024 16:47 ET
|
Arch Biopartners
TORONTO, July 30, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) today announced it has closed the non-brokered private placement...
Arch Biopartners Arranges Non-Brokered Private Placement
July 29, 2024 16:52 ET
|
Arch Biopartners
TORONTO, July 29, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) today announced it has arranged a non-brokered private placement...
Arch Biopartners Announces GMP Manufacturing of Cilastatin Drug Product
June 27, 2024 07:25 ET
|
Arch Biopartners
TORONTO, June 27, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced that Dalton Pharma Services (Dalton) has completed the...
AvePoint Named to Inc.’s Annual List of Best Workplaces for 2024
June 18, 2024 08:45 ET
|
AvePoint, Inc.
JERSEY CITY, N.J., June 18, 2024 (GLOBE NEWSWIRE) -- AvePoint (Nasdaq: AVPT), the global leader in robust data management and data governance, today announced it has been named to Inc.’s annual Best...
Arch Biopartners Announces University of Calgary Ethics Approval to Proceed with Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury (CS-AKI)
June 18, 2024 07:35 ET
|
Arch Biopartners
TORONTO, June 18, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that the University of Calgary’s Conjoint Health...
St. Michael’s Hospital Joins the Phase II Trial of LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury
April 16, 2024 07:14 ET
|
Arch Biopartners
TORONTO, April 16, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that a research team from St. Michael’s Hospital, a...